RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > Progress on the Development of a Benefit/Risk Framework for Evaluating Medicines

Progress on the Development of a Benefit/Risk Framework for Evaluating Medicines

Posted 01 March 2010 | By

Determining the benefit/risk (BR) balance of a new medicine is one of the most important steps in its development, review and postapproval reassessment. Recently, regulatory agencies and sponsors have begun to develop appropriate benefit/risk frameworks (BRFs) that enable collaborative scientific discussion of a product's therapeutic profile. Despite these early steps, there is room for improving communications among regulatory agencies and industry stakeholders. Specifically, there remains a need for clear, concise and unambiguous communication of findings about benefits and risks. The CMR International Institute for Regulatory Science (the Institute) recently convened a workshop to address the issues of improving communications regarding BR assessments within and across regional agencies and industry organizations.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.